Company / Total Assets
Enliven Therapeutics, Inc. Total Assets History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$325.8M
FY2024
5-year range
$83.3M / $325.8M
FY2020-FY2024
Trend
+19.8%
vs FY2023
Sector context
#179 of 214
Health Care
What the data says
Enliven Therapeutics, Inc.'s total assets of $326M is lower than 84% of companies in the Health Care sector (FY2024). Improved from $83M to $326M over the past 2 years.
Based on SEC 10-K filings.
$326M in FY2024 with a 5-year CAGR of +57.8%.
Improved from $83M to $326M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +51.5%
- 5-Year CAGR
- +57.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 214This company $325.8M Sector average $7.5B
▼
-95.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +57.8%, indicating consistent growth.
- In FY2024, total assets increased 19.8% year-over-year.
- Ranks #179 out of 214 companies in the Health Care sector.
- Lowest total assets in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $325.8M | +19.8% |
| FY2023 | $271.9M | +226.4% |
| FY2022 | $83.3M | -11.1% |
| FY2021 | $93.6M | +3.1% |
| FY2020 | $90.8M | +172.8% |
| FY2019 | $33.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026